Grabar Law Office

SPECIALIZING IN ANTITRUST, SECURITIES, AND CONSUMER CLASS ACTION LITIGATION. OFFERING CLIENTS EXPERT LEGAL ADVICE AND VALUE-ADDED SOLUTIONS.

SPECIALIZING IN ANTITRUST, SECURITIES, AND CONSUMER CLASS ACTION LITIGATION. OFFERING CLIENTS EXPERT LEGAL ADVICE AND VALUE-ADDED SOLUTIONS.

EXPERIENCE YOU CAN TRUST

Grabar Law Office

The firm specializes in complex, commercial litigation. The firm's principal, Joshua H. Grabar, has been involved in some of the largest class actions of the last two decades.

DEDICATION YOU CAN RELY ON

Grabar Law Office

We take pride in providing effective and aggressive representation. Our reputation and history of success speaks for itself and drives lasting client relationships. We are here for you.

LET'S WORK TOGETHER

Grabar Law Office

If you have suffered a financial loss as a result of securities fraud, price-fixing or consumer fraud, you can rest assured that we are on your side. If you are a business seeking to avoid unnecessary legal liability, or reduce the costs of compliance, we are your solution.

latest blog

Grabar Law Office

GRABAR LAW OFFICE INVESTIGATES POTENTIAL CLAIMS AGAINST OFFICERS AND DIRECTORS OF VOLTA, INC.  (NYSE: VLTA)

A federal securities fraud class action against complaint has been filed Against Volta, Inc. and certain of its officers and directors.  The complaint alleges that from August 2, 2021 to March 28, 2022, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Volta had improperly accounted for restricted stock units issued…
Read More
Grabar Law Office

GRABAR LAW OFFICE INVESTIGATES POTENTIAL CLAIMS AGAINST OFFICERS AND DIRECTORS OF ODONATE THERAPEUTICS, INC. AFTER AN AGREEMENT IS REACHED TO SETTLE CLASS ACTION

Odonate Therapeutics Inc. (OTC: ODTC) has agreed to pay $12.5 million to resolve a proposed securities class action in alleging the pharmaceutical company misled investors about the safety of a new drug for treating cancer. The lawsuit accused the company of making misleading statements and omissions about the development of tesetaxel. The amended complaint says…
Read More

GRABAR LAW OFFICE FILES COMPLAINT PURSUANT TO 8 DEL. C. § 220 TO COMPEL INSPECTION OF BOOKS AND RECORDS OF CLOVER HEALTH INVESTMENTS CORP.

Plaintiff wishes to inspect books and records relating to meetings of Clover Health’s Board of Directors (the “Board”) regarding materially false and misleading statements concerning the Company’s business and regulatory compliance. The Complaint alleges that company representatives including board chairman Chamath Palihapitiya made false and misleading statements about the company’s business and regulatory standing, leading…
Read More

GRABAR LAW OFFICE FILES COMPLAINT PURSUANT TO 8 DEL. C. § 220 TO COMPEL INSPECTION OF BOOKS AND RECORDS OF QUANTUMSCAPE CORPORATION

According to the Complaint, Plaintiff wishes to inspect books and records relating to meetings of QuantumScape’s Board of Directors (the “Board”) regarding materially false and misleading statements concerning the Company’s solid-state batteries. As alleged, public information about QuantumScape and its directors’ materially false and misleading statements supplies a credible basis to suspect wrongdoing that warrants…
Read More